Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stock Watch

Set Alert for Stock Watch

Stock Watch: Poxel Passes Go…But To Where?

Poxel’s shift to new therapeutic areas may be necessary despite Japan’s approval for its diabetes drug. Twymeeg looks set to be hamstrung by placebo-controlled studies without outcomes data.

Approvals Commercial

Stock Watch: Why Have Biotech Acquisitions Paused?

The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.

M & A Stock Watch

Stock Watch: Not So Fast, Gene Editors

Intellia’s announcement of the first in vitro gene editing proof of principle sent shockwaves through the life science investment space. But are there still many known unknowns.

Stock Watch Research & Development

Stock Watch: Gaming The US Health Care System

The pharmaceutical sector is often unfairly demonized in the drug pricing debate. Other participants exploit the complex US health care system almost with impunity.

Healthcare Systems Pricing Debate

Stock Watch: A Short History Of Placebo Approvals

Biogen’s recent contentious approval put the cat amongst the pigeons in the debate on surrogate markers as a basis for accelerated approval. The history of such approvals goes back to the last century.

Approvals Commercial

Stock Watch: Post-Pandemic Life Science Market Dynamics

Factors in addition to the rejuvenation of pharmaceutical revenues and biotechnology product failures are likely to pull in opposite directions at the sector’s recovery from the pandemic.

Stock Watch Companies

Stock Watch: Class Of 2016 FDA Approvals

Revenues are still elusive for a surprising number of the novel drugs approved by the FDA five years ago. Emergent safety issues and confirmatory clinical trial failures were less common than lack of competitiveness as the main reason for revenue weakness.

Sales & Earnings Stock Watch

Stock Watch: Veklury Peaks And Leaves Gilead In The Lurch

Veklury rescued Gilead’s weak underlying first-quarter performance. But the pandemic and its associated behavioral effects, as well as patent expiries, will continue to drag. 

Sales & Earnings Stock Watch

Stock Watch: Pandemic Lessons For Smaller Commercial Biotechs

Recently launched branded drugs prescribed by specialist physicians and marketed by smaller commercial-stage biotech companies remain in the eye of the pandemic storm.

Stock Watch Sales & Earnings

Stock Watch: The Rise Of Vaccine Cannibalism

Influenza and pneumococcal vaccine sales were initially strong at the start of the pandemic. Recent weak revenues for travel, childhood and premium vaccines could raise population immunity concerns, however.

Vaccines Sales & Earnings

Stock Watch: Rollercoaster For Pfizer; Doldrums For Esperion

An early high for Pfizer with its strong first-quarter results was followed by patent waiver worries. At the other end of the spectrum, Esperion reminded us of the challenges in making a commercial success as a small biopharma firm in the pandemic.

Sales & Earnings Coronavirus COVID-19

Stock Watch: Novartis And Lilly Pour Cold Water On Q1 Earnings

Novartis’s comparatively anemic revenue growth and Lilly’s sales shortfall suggest that hopes for an immediate sector recovery from the pandemic are premature.

Stock Watch Companies
UsernamePublicRestriction

Register